Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

PMID:
18375898
2.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
3.

Pemetrexed: a multitargeted antifolate.

Rollins KD, Lindley C.

Clin Ther. 2005 Sep;27(9):1343-82. Review.

PMID:
16291410
4.

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A.

Lung Cancer. 2011 Apr;72(1):73-7. doi: 10.1016/j.lungcan.2010.12.004. Epub 2011 Jan 8.

PMID:
21216487
5.

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.

Clin Cancer Res. 2005 Feb 1;11(3):982-92.

6.

Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.

Steer J, Bough G, Razak AR, Meachery GJ, Hughes A.

Clin Oncol (R Coll Radiol). 2010 Apr;22(3):231-5. doi: 10.1016/j.clon.2010.01.009.

PMID:
20346340
7.

Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.

Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.

J Clin Oncol. 2003 Apr 15;21(8):1556-61.

PMID:
12697881
8.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H.

J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17. Erratum in: J Clin Oncol. 2010 Jan 1;28(1):182. Winquist, Eric [added].

PMID:
19687335
9.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
10.

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.

J Clin Oncol. 2006 Mar 20;24(9):1443-8.

PMID:
16549838
11.

Second-line treatment for malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.

Cancer Treat Rev. 2010 Feb;36(1):24-32. doi: 10.1016/j.ctrv.2009.09.003. Epub 2009 Oct 29. Review.

PMID:
19879055
12.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
13.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

14.

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.

Respir Med. 2010 Jan;104(1):142-8. doi: 10.1016/j.rmed.2009.07.019. Epub 2009 Oct 8.

15.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.

PMID:
20177021
16.

[Update of pemetrexed in thoracic oncology].

Brechot JM, Morère JF.

Bull Cancer. 2007;94 Spec No Actualites:S139-41. Review. French.

PMID:
17845984
17.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
18.
19.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA; Pemetrexed Expanded Access Program Investigators.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.

PMID:
17092602
20.

Overview on ongoing or planned clinical trials in Europe.

Favaretto A.

Lung Cancer. 2005 Jul;49 Suppl 1:S117-21. Epub 2005 Apr 9. Review.

PMID:
15950791

Supplemental Content

Support Center